Diabetic macular edema: evidence-based management
DJ Browning, MW Stewart, C Lee - Indian journal of …, 2018 - journals.lww.com
Diabetic macular edema (DME) is the most common cause of vision loss in patients with
diabetic retinopathy with an increasing prevalence tied to the global epidemic in type 2 …
diabetic retinopathy with an increasing prevalence tied to the global epidemic in type 2 …
Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases
Anti-vascular endothelial growth factors (anti-VEGF) have become the most common
treatment modality for many retinal diseases. These include neovascular age-related …
treatment modality for many retinal diseases. These include neovascular age-related …
[HTML][HTML] Early and long-term responses to anti–vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data
VH Gonzalez, J Campbell, NM Holekamp, S Kiss… - American journal of …, 2016 - Elsevier
Purpose To determine whether early visual acuity response to ranibizumab in diabetic
macular edema is associated with long-term outcome. Design Post hoc analysis of …
macular edema is associated with long-term outcome. Design Post hoc analysis of …
Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes
TA Ciulla, JS Pollack, DF Williams - British Journal of Ophthalmology, 2021 - bjo.bmj.com
Background/Aim To assess visual acuity (VA) outcomes and antivascular endothelial growth
factor (anti-VEGF) treatment intensity in diabetic macular oedema (DMO). Methods …
factor (anti-VEGF) treatment intensity in diabetic macular oedema (DMO). Methods …
Real-world outcomes of anti–vascular endothelial growth factor therapy in diabetic macular edema in the United States
TA Ciulla, P Bracha, J Pollack, DF Williams - Ophthalmology Retina, 2018 - Elsevier
Purpose This study assessed real-world visual acuity (VA) outcomes of anti–vascular
endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME). Design …
endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME). Design …
Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1)
KJ Blinder, PU Dugel, S Chen, JM Jumper… - Clinical …, 2017 - Taylor & Francis
Purpose To evaluate the efficacy, safety, and injection frequency of vascular endothelial
growth factor (VEGF) inhibitors as used in clinical practice for the treatment of diabetic …
growth factor (VEGF) inhibitors as used in clinical practice for the treatment of diabetic …
[HTML][HTML] Vision outcomes following anti–vascular endothelial growth factor treatment of diabetic macular edema in clinical practice
NM Holekamp, J Campbell, A Almony… - American journal of …, 2018 - Elsevier
Purpose To determine monitoring and treatment patterns and vision outcomes in real-world
patients initiating anti–vascular endothelial growth factor (anti-VEGF) therapy for diabetic …
patients initiating anti–vascular endothelial growth factor (anti-VEGF) therapy for diabetic …
Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice
MH Maloney, SR Payne, J Herrin, LR Sangaralingham… - Ophthalmology, 2021 - Elsevier
Purpose Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy plays a
central role in the management of neovascular age-related macular degeneration (nAMD) …
central role in the management of neovascular age-related macular degeneration (nAMD) …
[HTML][HTML] Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions
VS Kansara, SE Hancock, LW Muya… - Journal of Controlled …, 2022 - Elsevier
Drug delivery to the suprachoroidal space (SCS®) has become a clinical reality after the
2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for …
2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for …
A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema
DG Callanan, A Loewenstein, SS Patel… - Graefe's archive for …, 2017 - Springer
Purpose To evaluate whether treatment with dexamethasone intravitreal implant (DEX
implant) 0.7 mg every 5 months provides a similar average change in best-corrected visual …
implant) 0.7 mg every 5 months provides a similar average change in best-corrected visual …